A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

Clinical trial NCT07681271 · RECRUITING

Trial details

NCT number: NCT07681271
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Papulopustular Rosacea

Start date: 2026-07-30
Primary completion: 2027-12-07
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.